The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Lysophospholipid receptors in drug discovery
Open accessAbstract
Lysophospholipids (LPs), including lysophosphatidic acid (LPA), sphingosine 1-phospate (S1P), lysophosphatidylinositol (LPI), and lysophosphatidylserine (LysoPS), are bioactive lipids that transduce signals through their specific cell-surface G protein-coupled receptors, LPA1–6, S1P1–5, LPI1, and LysoPS1–3, respectively. These LPs and their receptors have been implicated in both physiological and pathophysiological processes such as autoimmune diseases, neurodegenerative diseases, fibrosis, pain, cancer, inflammation, metabolic syndrome, bone formation, fertility, organismal development, and other effects on most organ systems. Advances in the LP receptor field have enabled the development of novel small molecules targeting LP receptors for several diseases. Most notably, fingolimod (FTY720, Gilenya, Novartis), an S1P receptor modulator, became the first FDA-approved medicine as an orally bioavailable drug for treating relapsing forms of multiple sclerosis. This success is currently being followed by multiple, mechanistically related compounds targeting S1P receptor subtypes, which are in various stages of clinical development. In addition, an LPA1 antagonist, BMS-986020 (Bristol-Myers Squibb), is in Phase 2 clinical development for treating idiopathic pulmonary fibrosis, as is a distinct compound, SAR100842 (Sanofi) for the treatment of systemic sclerosis and related fibrotic diseases. This review summarizes the current state of drug discovery in the LP receptor field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Sphingosine-1-phosphate signaling and its role in disease
Maceyka, M., Harikumar, K. B., Milstien, S., & Spiegel, S. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.003 · Cited by 1,039
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Self-citationGPR34 is a receptor for lysophosphatidylserine with a fatty acid at the sn-2 position
Kitamura, H., Makide, K., Shuto, A., Ikubo, M., Inoue, A., Suzuki, K., Sato, Y., Nakamura, S., Otani, Y., Ohwada, T., et al. (2012) · The Journal of Biochemistry · doi:10.1093/jb/mvs011 · Cited by 86
Cited by
Emerging roles of lysophospholipids in health and disease
Tan, S. T., Ramesh, T., Toh, X. R., & Nguyen, L. N. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101068 · Cited by 371
Lysophosphatidic Acid Signaling in the Nervous System
Yung, Y. C., Stoddard, N. C., Mirendil, H., & Chun, J. (2015) · Neuron · doi:10.1016/j.neuron.2015.01.009 · Cited by 263
Self-citationChun, J., Kihara, Y., Jonnalagadda, D., & Blaho, V. A. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021358 · Cited by 131
Self-citationDusaban, S. S., Chun, J., Rosen, H., Purcell, N. H., & Brown, J. H. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0882-x · Cited by 106
Self-citationHollands, A., Corriden, R., Gysler, G., Dahesh, S., Olson, J., Raza Ali, S., Kunkel, M. T., Lin, A. E., Forli, S., Newton, A. C., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.695866 · Cited by 73
Metadata
- Authors
- Kihara, Y., Mizuno, H., & Chun, J.
- Venue
- Experimental Cell Research
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 333
- Issue
- 2
- Pages
- 171-177
- ISSN
- 0014-4827 (ISSN-L)
- OpenAlex
- W1985551319
- Cited by
- 189
- References
- 5
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lysophospholipid receptors in drug discovery. https://app.cochat.ai/papers/10.1016/j.yexcr.2014.11.020
- The paper
- Kihara, Y., Mizuno, H., & Chun, J. (2015). Lysophospholipid receptors in drug discovery. Experimental Cell Research. https://doi.org/10.1016/j.yexcr.2014.11.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.